Cardiology Medical News about Cardiovascular Diseases

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Pazopanib Approved for Advanced Kidney Cancer

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Hedgehog Pathway Inhibitor Shrinks Medulloblastoma

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The value of drugs for obesity in the management of cardiovascular risk factors
Sang Thrombose Vaisseaux, 11/04/09

Czernichow S et al. – Clinical trials show that the expected weight loss is 3 to 4 Kg compared with placebo. In addition, orlistat should improve blood sugar and lipid levels and reduce blood pressure. Sibutramine increases HDL cholesterol, decreases triglycerides but increases the blood pressure and heart rate. A trial is underway to study the impact of these adverse effects in subjects at high cardiovascular risk. Therefore, the field for the development of new drugs for treating overweight and obesity remains wide open.

<< Previous
Pharmaco-active stents

Next >>
The electrocardiogram in left ventricular hypertrophy: past and...